Sudarshan Pharma Industries Limited
NSE: SUDARSHAN · Specialty Chemicals
Share price ₹29.90
down 3.36% · close of 20 Nov 2026
Your ratios
Market cap
₹761 Cr
P/E ratio
26.2
EPS TTM to Sep 2026
P/B ratio
3.9
ROCE
15.2%
ROE
16.3%
Dividend yield
0.0%
as of 20 Nov 2026
1 · Overview
Overview
Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.
One candle a week · body: open to close, green when it closed higher · line: high to low
At a glance · 1Yr
Every small chart follows the range above. Point at it to read a value; click it to open it.2 · Results
Latest result · Q2 FY27
What the last results showed. Whether management kept its word is in Pro.
Net profit ₹7.78 Cr, up 101.0% on Sep 2025
7 years, Mar 2020 to Mar 2026, and the last 12 months · key lines
| Line | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 | TTMto Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales₹ crore | 148.00 | 193.00change on a year before +30% | 357.00change on a year before +85% | 461.00change on a year before +29% | 464.00change on a year before +1% | 505.04change on a year before +9% | 703.06 | 780.32change on a year before +32% |
| Expenses₹ crore | 143.00 | 186.00 | 346.00 | 446.00 | 441.00 | 465.00 | 651.74 | 712.76 |
| Material cost₹ crore | 39.06 | |||||||
| Change in inventories₹ crore | -71.81 | |||||||
| Goods bought for resale₹ crore | 652.13 | |||||||
| Employee cost₹ crore | 7.44 | |||||||
| Other expenses₹ crore | 24.93 | |||||||
| Operating profit₹ crore | 5.00 | 7.00change on a year before +40% | 11.00change on a year before +57% | 15.00change on a year before +36% | 23.00change on a year before +53% | 40.00change on a year before +74% | 51.32 | 67.56change on a year before +53% |
| Operating margin% of sales | 3.20% | 3.70% | 3.10% | 3.20% | 4.90% | 8.00% | 7.30% | 8.66% |
| Gross margin% of sales | 11.90% | |||||||
| Other income₹ crore | 0.00 | 0.00 | 0.00 | 1.00 | 3.00 | 0.00 | 8.71 | 8.80 |
| Interest₹ crore | 3.00 | 3.00 | 3.00 | 5.00 | 9.00 | 16.00 | 25.70 | 32.38 |
| Depreciation₹ crore | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 3.79 | 4.77 |
| Profit before tax₹ crore | 2.00 | 4.00 | 7.00 | 9.00 | 15.00 | 22.00 | 30.54 | 39.21 |
| Tax rate% of profit before tax | 26.00% | 25.00% | 26.00% | 26.00% | 25.00% | 26.00% | 23.00% | |
| Net profit₹ crore | 1.00 | 3.00change on a year before +200% | 5.00change on a year before +67% | 7.00change on a year before +40% | 11.00change on a year before +57% | 16.00change on a year before +45% | 23.37 | 28.94change on a year before +60% |
| EPS₹ per share | 0.07 | 0.16change on a year before +129% | 0.31change on a year before +94% | 0.29change on a year before -6% | 0.48change on a year before +66% | 0.66change on a year before +38% | 0.97 | 1.17change on a year before +52% |
| Dividend paid out% of net profit | 0.00% | 0.00% | 0.00% | 10.00% | 0.00% | 0.00% | 0.00% |
Small figure: change on the year before (TTM: on the 12 months to Sep 2025). TTM = the four quarters to Sep 2026. Lines that are 0 or blank in every column are not shown.
The last 10 quarters, Jun 2024 to Sep 2026 · key lines
| Line | Jun 2024Q1 FY25 | Sep 2024Q2 FY25 | Dec 2024Q3 FY25 | Mar 2025Q4 FY25 | Jun 2025Q1 FY26 | Sep 2025Q2 FY26 | Dec 2025Q3 FY26 | Mar 2026Q4 FY26 | Jun 2026Q1 FY27 | Sep 2026Q2 FY27 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales₹ crore | 99.20 | 128.58 | 115.66 | 161.59 | 145.26change on a year before +46% | 168.87change on a year before +31% | 168.01change on a year before +45% | 220.92change on a year before +37% | 174.42change on a year before +20% | 216.97change on a year before +28% |
| Expenses₹ crore | 97.12 | 115.53 | 107.69 | 145.66 | 134.22 | 159.66 | 157.14 | 200.72 | 158.52 | 196.38 |
| Material cost₹ crore | 7.26 | |||||||||
| Change in inventories₹ crore | -15.55 | |||||||||
| Goods bought for resale₹ crore | 192.13 | |||||||||
| Employee cost₹ crore | 2.04 | |||||||||
| Other expenses₹ crore | 10.51 | |||||||||
| Operating profit₹ crore | 2.08 | 13.05 | 7.97 | 15.93 | 11.04change on a year before +431% | 9.21change on a year before -29% | 10.87change on a year before +36% | 20.20change on a year before +27% | 15.90change on a year before +44% | 20.59change on a year before +124% |
| Operating margin% of sales | 2.10% | 10.15% | 6.89% | 9.86% | 7.60% | 5.45% | 6.47% | 9.14% | 9.12% | 9.49% |
| Gross margin% of sales | 15.27% | |||||||||
| Other income₹ crore | 0.98 | -0.85 | 0.51 | -0.81 | 1.21 | 1.86 | 1.52 | 4.13 | 1.22 | 1.93 |
| Interest₹ crore | 3.94 | 3.70 | 4.00 | 4.40 | 5.96 | 5.94 | 6.28 | 7.53 | 8.21 | 10.36 |
| Depreciation₹ crore | 0.67 | 0.67 | 0.63 | 0.83 | 0.88 | 0.90 | 0.91 | 1.09 | 1.41 | 1.36 |
| Profit before tax₹ crore | -1.55 | 7.83 | 3.85 | 9.89 | 5.41 | 4.23 | 5.20 | 15.71 | 7.50 | 10.80 |
| Tax rate% of profit before tax | -21.94% | 24.90% | 24.94% | 25.08% | 26.80% | 8.51% | 20.19% | 27.43% | 25.33% | 27.96% |
| Net profit₹ crore | -1.21 | 5.88 | 2.88 | 7.41 | 3.96 | 3.87change on a year before -34% | 4.15change on a year before +44% | 11.40change on a year before +54% | 5.61change on a year before +42% | 7.78change on a year before +101% |
| EPS₹ per share | -0.05 | 0.24 | 0.12 | 0.31 | 0.17 | 0.17change on a year before -29% | 0.18change on a year before +50% | 0.45change on a year before +45% | 0.23change on a year before +35% | 0.31change on a year before +82% |
| Diluted EPS₹ per share | 0.31 |
Small figure: change on the same quarter a year earlier. Lines that are 0 or blank in every column are not shown.
Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.
Sales
a year, compounded
- 5 years
- 30%
- 3 years
- 15%
- TTM
- 32%
Profit
a year, compounded
- 5 years
- 54%
- 3 years
- 48%
- TTM
- 45%
Share price
a year, compounded
- 3 years
- 56%
- 1 year
- 29%
Return on equity
average over the span
- 5 years
- 14%
- 3 years
- 14%
- Last year
- 16%
3 · Quality & value
Answers
The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.
How fast it has been growing
Fewer than three years of filings — too early to judge growth.
Whether it grew faster than its sector
It grew 15.1% a year against a sector median of 1.7% — 13.4 percentage points faster.
Room to re-rate, or risk of de-rating
At 26.2× earnings against a market that pays 23.0× across 2,280 companies we can price.
Its own industry sits at 56.4×, across 5 companies. It is against its own five-year median of 33.3×, the 16th percentile of its own range.
Whether growth justifies the valuation
Priced at 0.5 times its growth rate, on earnings growth of 47.8%.
P/E ÷ profit growth a year (3 years). A dash: no profit growth to divide by.
How it compares with its peers
Against companies the exchange files under the same label (Specialty Chemicals), it ranks 29 of 79 on returns, 58 of 78 on margin.
A longer bar is a better rank.
What makes it hard to beat — and is that still true?
A narrow advantage: it earns 15.2% on capital, ahead of 63% of companies filed under the same label.
Whether its growth pays for itself
No — Over the last five years the business itself consumed ₹61 crore of cash before any plant spend, funded mostly borrowed — borrowings rose from ₹31 crore to ₹285 crore.
And the profit is not backed by cash: it reported a profit over 7 years and consumed cash from the business. Its cash comes back faster than it used to: it went from waiting 27 days for its cash to waiting 17 days for its cash.
Peers here are the 79 companies the exchange files under the same label (Specialty Chemicals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.
Business score & profit checks
How strong the business is, and whether its profit is real cash. Facts only, not advice.
Business score
62 out of 100
How strong the business is, in one number. Last changed 20 Nov 2026.
Profit checks: is the profit real cash?
6 of 8 checks clear
2 of 10 checks could not be run.
Simple checks on the accounts. Which 2 are flagged is in Pro.
Key numbers & peers
Grouped by topic. Each number says what period it is for.
Price
- Market cap
- ₹761 Cr
- Prev close
- ₹29.90
- 52w High
- ₹42.8
- 52w Low
- ₹18.5
- Beta
- 0.5
- Price CAGR 1y
- 29.0%
- Price CAGR 3y
- 56.0%
- Price CAGR 5y
- —
- Price CAGR 10y
- —
Valuation
- P/E ratioEPS TTM to Sep 2026
- 26.2
- Industry P/E
- 25.8
- P/B ratio
- 3.9
- EV / EBITDA
- 15.5
- Enterprise value
- ₹1,045 Cr
- PEG ratio
- 0.5
- Dividend yield
- 0.0%
Returns
- ROCE
- 15.2%
- ROCE 5y average
- 15.8%
- ROE
- 16.3%
- ROE 3y average
- 14.0%
- ROE last year
- 16.0%
- Return on assets
- 3.6%
Sales, profit & margins
- Annual revenue
- ₹703 Cr
- Annual profit
- ₹23.4 Cr
- EPS
- ₹1.0
- Operating margin
- 7.3%
- Net profit margin
- 3.3%
- EBITDA margin
- 7.3%
- Sales latest quarterSep 2026 quarter
- ₹217 Cr
- Profit latest quarterSep 2026 quarter
- ₹7.78 Cr
- OPM latest quarterSep 2026 quarter
- 9.5%
Growth a year
- Sales growth 3y
- 15.1%
- Sales growth 5y
- 29.5%
- Sales growth TTM
- 32.0%
- Profit growth 3y
- 47.8%
- Profit growth 5y
- 54.2%
- Profit growth TTM
- 45.4%
- YoY quarterly sales growthSep 2026 vs Sep 2025
- 28.5%
- YoY quarterly profit growthSep 2026 vs Sep 2025
- 101.0%
Balance sheet
- Book Value
- ₹7.7
- Face Value
- ₹1.0
- Borrowings
- ₹285 Cr
- Total debt
- ₹392 Cr
- Total cash
- ₹1.00 Cr
- Net debtas of 31 Mar 2026
- ₹284 Cr
- Debt / Equity
- 2.0
- Interest coverage
- 2.2
- Reserves / Equity
- 5.5
Cash & payout
- Operating cash flow
- -₹2.00 Cr
- Free cash flow
- -₹51.1 Cr
- FCF yield
- -10.1%
- Net cash flow
- -₹1.00 Cr
- Dividend payout
- 0.0%
- Revenue per employeeyear to 31 Mar 2026
- ₹10.43 Cr
Holdings
- Promoter holding
- 57.8%
- FII holding
- 21.9%
- DII holding
- —
- Public holding
- 20.2%
Enterprise value, step by step
What buying the whole company would cost: its market value, less the cash it holds over its debt. Net debt from the balance sheet of 31 Mar 2026.
- Market cap₹761 Cr
- +Net debt₹284 Cr
- =Enterprise value₹1,045 Cr
Peers
| Company | Price ₹ | P/E | Mkt cap ₹ Cr | Div yield | Profit qtr ₹ Cr | Profit change | Sales qtr ₹ Cr | Sales change | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Pidilite Industries | 1,620.00 | 61.5 | 1,64,997 | 0.74% | 626 | +7.09% | 4,298 | +20.91% | 31.58% |
| Gujarat Fluorochemicals Limited | 4,932.70 | 78.3 | 54,260 | 0.06% | 240 | +34.08% | 1,760 | +45.45% | 9.69% |
| Navin Fluorine International Limited | 10,077.00 | 56.4 | 51,695 | 0.15% | 269 | +81.91% | 1,191 | +57.00% | 21.37% |
| Aether Industries Limited | 1,620.30 | 85.3 | 21,506 | 0.00% | 68.0 | +25.93% | 347 | +23.88% | 11.92% |
| Deepak Nitrite Limited | 1,531.20 | 19.5 | 20,886 | 0.47% | 398 | +234.18% | 3,076 | +61.75% | 11.59% |
| Fine Organic Industries Limited | 5,488.50 | 34.9 | 16,828 | 0.20% | 152 | +39.56% | 729 | +22.12% | 21.47% |
| Aarti Industries Limited | 449.50 | 26.9 | 16,305 | 0.22% | 168 | +58.49% | 3,669 | +74.71% | 6.85% |
| Sudarshan Pharma Industries Limited | 29.90 | 26.2 | 761 | 0.00% | 7.78 | +101.04% | 217 | +28.48% | 15.16% |
| Medianof the whole group of 79, 20 Nov 2026 | 26.4 | 0.29% | +37.60% | +27.01% | 11.59% |
Median: the middle value of the whole peer group of 79 companies. Price and rupee sizes are left blank there, as a middle value of those says little.
4 · Balance sheet & cash
Balance sheet
What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.
At Mar 2026: ₹642 cr of assets, and who funds them
Shareholders’ own money funds 24% of it; borrowings 44%.
What it owns
- Fixed assets ₹104 cr 16%
- Being built ₹3.00 cr 0%
- Everything else ₹535 cr 83%
Who funds it
- Shareholders’ money ₹155 cr 24%
- Borrowings ₹285 cr 44%
- Everything else ₹202 cr 31%
Each year end. Newest year end shaded.
| Line, ₹ crore | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|---|---|---|---|---|
| Equity capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 131 |
| Borrowings | 21 | 30 | 31 | 34 | 105 | 171 | 285 |
| Other liabilities | 18 | 47 | 77 | 97 | 67 | 100 | 202 |
| Total funding | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
| Fixed assets | 6 | 6 | 6 | 20 | 26 | 48 | 104 |
| Being built (CWIP) | 0 | 0 | 1 | 0 | 2 | 23 | 3 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 0 |
| Other assetsreceivables, cash, rest | 53 | 93 | 131 | 200 | 242 | 302 | 534 |
| Total assets | 58 | 99 | 138 | 232 | 283 | 402 | 642 |
Cash flows
Real money coming in and going out — from the business, from investments and from loans. ₹ crore.
Pick a period to see where its cash went.
In words
- The business used ₹2.30 cr more than it brought in.
- It put ₹78.0 cr into assets and investments.
- It raised ₹79.0 cr from shareholders and lenders.
- Cash in hand fell by ₹1.00 cr. Free cash flow: −₹50.8 cr.
| Line, ₹ crore | Mar 2020FY20 | Mar 2021FY21 | Mar 2022FY22 | Mar 2023FY23 | Mar 2024FY24 | Mar 2025FY25 | Mar 2026FY26 |
|---|---|---|---|---|---|---|---|
| From the business | 1.00 | 3.00 | -4.00 | -29.00 | 6.00 | -32.00 | -2.30 |
| From investing | -3 | -1 | -1 | -26 | -5 | -21 | -78 |
| From financingdividends, buybacks, loans | 0 | -1 | 4 | 66 | -12 | 53 | 79 |
| Net change in cash | -2 | 0 | -1 | 11 | -12 | 0 | -1 |
| Free cash flow | -4.00 | 1.00 | -5.00 | -43.00 | 2.00 | -54.00 | -50.84 |
| Cash ÷ operating profitbefore tax | 20.00% | 43.00% | -36.00% | -193.00% | 26.00% | -80.00% | -4.00% |
Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.
Efficiency ratios
How fast customers pay and how well capital earns. Each year, Mar 2020 to Mar 2026.
Debtor days
121 days
Days customers take to pay. Lower is faster.
121 days in FY26, against 116 days in FY25. Over these 7 years: 65 days (FY23) to 121 days (FY26).
Inventory days
129 days
Days stock sits before it is sold.
129 days in FY26, against 117 days in FY25. Over these 7 years: 46 days (FY20) to 129 days (FY26).
Days payable
111 days
Days it takes to pay its suppliers.
111 days in FY26, against 76 days in FY25. Over these 7 years: 40 days (FY20) to 111 days (FY26).
Cash conversion cycle
139 days
Debtor days plus inventory days, less days payable.
139 days in FY26, against 156 days in FY25. Over these 7 years: 46 days (FY22) to 156 days (FY25).
Working capital days
17 days
Days of sales tied up in running the business.
17 days in FY26, against 52 days in FY25. Over these 7 years: 17 days (FY26) to 62 days (FY24).
Return on capital (ROCE)
15%
Operating profit on the capital used.
15% in FY26, against 16% in FY25. Over these 6 years: 14% (FY24) to 19% (FY22).
5 · Owners & payouts
Dividends, splits & big trades
Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.
Dividend a share, by the year of its ex-date
No dividend on record.
Share of profit paid as dividend
Each year, Mar 2020 to Mar 2026.
Splits, bonuses & buybacks
- Split or bonus 1:1022 Nov 2024
Big trades by funds and insiders
None listed for this company.
6 · Price & trading
Open interestPRO
Where option traders are positioned on this stock.
7 · Business
About
What the company is, from our own records: where it sits, where its revenue comes from, and where it works.
- Sector
- Chemicals
- Industry
- Specialty Chemicals
- Symbol
- SUDARSHAN
- ISIN
- INE00TV01023
Sites · 6
- Mahad Unit IIMahad, Maharashtra
- Plant 2 - Turbhe UnitTurbhe, Maharashtra
- Plant 3Gujarat, Gujarat
- Srigen API FacilityMedchal, Telangana
- Unit 2Palghar, Maharashtra
- Wada PlantWada, Maharashtra
Industry numbers
The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.
Main figures
- Exports share of revenue3.46%
Brand spend
- Ad spendFY to Mar 20260.00%
Revenue and margin
- EBIT marginSep 2026 quarter8.87%
Working capital
- Days sales outstanding12 months to Sep 2026117 days
- Customer advancesFY to Mar 2026₹3.89 Cr
Costs
- Employee costSep 2026 quarter0.94%
Profit quality
- Other income shareSep 2026 quarter17.89%
- Interest coverSep 2026 quarter2.04x
Returns
- RoE12 months to Mar 202616.35%
- RoA12 months to Mar 20264.48%
- Sales to net block12 months to Sep 20267.88x
Leverage
- Net debt to EBITDA12 months to Mar 20265.53x
Growth
- Revenue growth (YoY)Sep 2026 quarter28.48%
Capex
- CapexFY to Mar 2026₹48.8 Cr
- Capex to revenueFY to Mar 20266.95%
How they have moved
EBIT margin · quarterly
Source: Computed from the filings
| Sep 26 | 8.87% | Computed from the filings |
| Jun 26 | 8.31% | Computed from the filings |
| Mar 26 | 8.65% | Computed from the filings |
| Dec 25 | 5.93% | Computed from the filings |
Other income share · quarterly
Source: Computed from the filings
| Sep 26 | 17.89% | Computed from the filings |
| Jun 26 | 16.27% | Computed from the filings |
| Mar 26 | 26.29% | Computed from the filings |
| Dec 25 | 29.23% | Computed from the filings |
Interest cover · quarterly
Source: Computed from the filings
| Sep 26 | 2.04x | Computed from the filings |
| Jun 26 | 1.91x | Computed from the filings |
| Mar 26 | 3.09x | Computed from the filings |
| Dec 25 | 1.83x | Computed from the filings |
Revenue growth (YoY) · quarterly
Source: Computed from the filings
| Sep 26 | 28.48% | Computed from the filings |
| Jun 26 | 20.07% | Computed from the filings |
| Mar 26 | 36.72% | Computed from the filings |
| Dec 25 | 45.26% | Computed from the filings |
Capex (fiscal year) · yearly
Source: Computed from the filings
| FY26 | ₹48.8 Cr | Computed from the filings |
| FY25 | ₹22.0 Cr | Computed from the filings |
| FY24 | ₹4.00 Cr | Computed from the filings |
Capex to revenue (fiscal year) · yearly
Source: Computed from the filings
| FY26 | 6.95% | Computed from the filings |
| FY25 | 4.36% | Computed from the filings |
| FY24 | 0.86% | Computed from the filings |
Supply chain
Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Sudarshan Pharma Industries Limited through this map.
Sells to · 23
- AFMSDPharmaceutical formulations and medicines
- Akzo NobelPharmaceutical formulations and specialty chemicals
- Asian PaintsSpecialty chemicals
- Astral PipesPharmaceutical formulations and specialty chemicals
- Bayer AGPharmaceutical formulations and specialty chemicals
- DuPontPharmaceutical formulations and specialty chemicals
- IntasPharmaceutical formulations and specialty chemicals
- Invision Life SciencesPharmaceutical formulations and specialty chemicals
- Jubilant Life SciencesPharmaceutical products
- L&T (Aeronautical division)Pharmaceutical formulations and medicines
+ 13 more
- LupinPharmaceutical products
- MinovaPharmaceutical formulations and specialty chemicals
- Muscat Pharmaceuticals Mfg. CoPharmaceuticals and specialty chemicals
- NikapharmaPharmaceuticals and specialty chemicals
- Omkar PharmaPharmaceutical formulations and specialty chemicals
- ReliancePharmaceutical formulations and specialty chemicals
- RemexPharmaceuticals and specialty chemicals
- Rose ChemicalsPharmaceuticals and specialty chemicals
- SRFPharmaceutical formulations and specialty chemicals
- SandozPharmaceutical products
- Suan Hong TradingPharmaceuticals and specialty chemicals
- Sun PharmaPharmaceutical products
- Teva PharmaPharmaceutical products
Uses as raw material · 1
- Active Pharmaceutical IngredientsFrom China
Exports to · 8
- Australia
- Bangladesh
- Oman
- Syria
- Taiwan
- United Arab Emirates
- United Kingdom
- Uzbekistan
Competes with · 7 companies
- Pidilite Industries
- Gujarat Fluorochemicals
- Navin Fluorine International
- Aether Industries
- Deepak Nitrite
- Fine Organic Industries
- Aarti Industries
Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.
8 · News & documents
News and what it reaches
Filings and news about Sudarshan Pharma Industries Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.
9 Nov 202618:10 IST
AI-written from public sources · Information, not advice · Not SEBI-registered
Documents
Earnings calls, results presentations and annual reports, straight from the company and the exchanges.
Annual reports · 1
Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.